Anergis SA
http://www.anergis.ch/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Anergis SA
Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Anergis And Virometix Collaborate On Fast-Acting Allergy Immunotherapy
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Sonica Health Develops Wearable For Early Warning Of COVID-19
The US government is helping Sonica develop ADAM, a patch monitor that tracks the user's breathing patterns and other physiologic signals to detect SARS-CoV-2 infections.
COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay
The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice